Research on the current situation and coping strategies for cervical cancer in China

Abstract

Cervical cancer caused by human papilloma virus has become one of the most common cancers threatening the life and health of Chinese women.The incidence and mortality of cervical cancer in China has always been high, and cervical cancer has become the sixth most common disease among Chinese women.In this paper, the status quo and existing problems of cervical cancer in China were analyzed, and combined with the actual work of the current immunization program, the vaccination rate of human papilloma virus vaccine was strengthened to help achieve the goal of eliminating cervical cancer.

The impact of exposure to HPV related information and injunctive norms on young women's intentions to receive the HPV vaccine in China: A structural equation model based on KAP theory

“…For instance, after the Changsheng vaccine incident in 2018, the public in China became skeptical about the vaccine safety and the reliability of vaccine suppliers, especially domestic vaccine manufacturers, and public confidence in the vaccination management system once dropped to a historically low level ( 70 ). The “Hong Kong gray-market HPV vaccines” incident in May 2019 has once again caused public doubts about HPV vaccine safety ( 71 ), which will seriously hamper the public vaccination in the future. Therefore, the relevant authorities need to consider the public's concerns about the vaccine by not only carrying out studies to test the safety and efficacy of vaccine, but also improving transparency on issues such as vaccine-related injuries and adverse reactions ( 72 ), thereby enhancing public trust in vaccine safety and reducing HPV vaccine hesitation.…”

Preference for human papillomavirus vaccine type and vaccination strategy among parents of school-age girls in Guangdong province, China

“…In comparison, in China, the HPV vaccination coverage remained rather low, despite all types of HPV vaccines (including domestic and imported bivalent and quadrivalent and imported nine-valent vaccines) being made available to females aged 9–45. By 2021, only 20 million out of 382 million Chinese females aged 9 to 45 received HPV vaccination ( Yuan et al, 2022 ). For girls aged 9–15, by 2020, the vaccination rate was less than 1% ( Center for Social Media Research School of New Media, 2020 ).…”